Local release of masitinib alters in vivo implantable continuous glucose sensor performance
Local release of masitinib alters in vivo implantable continuous glucose sensor performance
复制标题
DOI：
10.1016/j.bios.2015.08.059
复制
发表时间：
2016-03-15
影响因子：
12.6
通讯作者：
Solzbacher, F.
中科院分区：
文献类型：
--
作者：
Avula, M.;Jones, D.;Solzbacher, F.
Continuous glucose monitoring (CGM) sensors are often advocated as a clinical solution to improve longterm glycemic control in the context of diabetes. Subcutaneous sensor inflammatory response, fouling and fibrous encapsulation resulting from the host foreign body response (FBR) reduce sensor sensitivity to glucose, eventually resulting in sensor performance compromise and device failure. Several combination device strategies load CGM sensors with drug payloads that release locally to tissue sites to mitigate FBR-mediated sensor failure. In this study, the mast cell-targeting tyrosine kinase inhibitor, masitinib, was released from degradable polymer microspheres delivered from the surfaces of FDA-approved human commercial CGM needle-type implanted sensors in a rodent subcutaneous test bed. By targeting the mast cell c-Kit receptor and inhibiting mast cell activation and degranulation, local masitinib penetration around the CGM to several hundred microns sought to reduce sensor fibrosis to extend CGM functional lifetimes in subcutaneous sites. Drug-releasing and control CGM implants were compared in murine percutaneous implant sites for 21 days using direct-wire continuous glucose reporting. Drug-releasing implants exhibited no significant difference in CGM fibrosis at implant sites but showed relatively stable continuous sensor responses over the study period compared to blank microsphere control CGM implants. (C) 2015 Elsevier B.V. All rights reserved.
